Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMSC in Posterolateral Spinal Fusion for Degenerative Spine Disease
NCT03827096Phase 2Terminated
- Sponsor
- Bioinova
- Start
- Aug 2013
- Primary completion
- Dec 2016
01
Overview
Phase 2, open-label trial of autologous mesenchymal stem cells in degenerative disc disease (DDD), sponsored by Bioinova. Primary endpoint: Safety at 1 year. Started Aug 2013; status: terminated.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT03827096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827096.